Tenax Therapeutics Inc. (YBO0)
XFRA 
NASDAQ (CM) Primary XFRA Summary
YBO0 Chart
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tenax Therapeutics Inc. (YBO0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tenax Therapeutics Inc. ever had a stock split?
Tenax Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher T. Giordano CEO | XFRA Exchange | US88032L6056 ISIN |
| US Country | 15 Employees | - Last Dividend | 3 Jan 2024 Last Split | 2 Jan 1997 IPO Date |
Overview
Tenax Therapeutics, Inc. specializes in the development and commercialization of pharmaceutical products aimed at treating pulmonary arterial hypertension and associated conditions. Originally established as Oxygen Biotherapeutics, Inc., the company underwent a name change to Tenax Therapeutics, Inc. in September 2014 to better reflect its focused mission. With its foundation laid in 1967 and headquartered in Chapel Hill, North Carolina, Tenax Therapeutics has been at the forefront of creating innovative treatments designed to improve the quality of life for patients with complex cardiovascular diseases.
Products and Services
- TNX-101 (IV)
A phase II clinical trial product designed for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction. This innovative treatment aims to alleviate the symptoms and improve the overall health condition of patients suffering from this specific form of heart failure.
- TNX-102
Another advanced therapeutic under Tenax Therapeutics' portfolio, TNX-102 has successfully completed phase II clinical trials. It is also aimed at the treatment of pulmonary hypertension but focuses on patients dealing with heart failure with preserved ejection fraction and associated pulmonary hypertension, providing a broader approach to managing these conditions.
- TNX-103 (levosimendan)
Developed with a specific formulation, TNX-103 (levosimendan) targets pulmonary hypertension associated with heart failure with preserved ejection fraction. By completing phase II clinical trials, this drug aims to offer a new ray of hope for patients by treating the underlying heart conditions that contribute to pulmonary hypertension.
- TNX-201 (imatinib)
A critical addition to the portfolio, TNX-201 incorporates the use of imatinib, a tyrosine kinase inhibitor, offering a treatment solution for chronic myeloid leukemia. This highlights Tenax Therapeutics' versatility in addressing both cardiovascular and oncological health challenges through its product range.
